9.5 Ethical Considerations in Non-Healing Wounds & End-of-Life Skin Care

Ethical Considerations in Non-Healing Wounds & End-of-Life Skin Care

Wound management at the end of life presents complex bioethical challenges for Certified Wound Care Specialists. As patients experience multi-organ system failure, advanced malignancy, severe frailty, or terminal physiological decline, the skin—the body's largest organ—frequently undergoes systemic vascular failure. In these clinical scenarios, aggressive curative wound interventions (such as painful surgical debridements, frequent disruptive dressing changes, or rigid offloading regimens that cause distress) may conflict with the patient's overall goals of care. Clinicians must apply bioethical frameworks to transition care smoothly from curative healing to palliative wound management.

---

Bioethical Principles in Wound Care Practice

Resolving complex wound care dilemmas requires balancing the four fundamental bioethical principles:

1. Beneficence (Doing Good): Acting in the patient's best interest. In curative settings, beneficence means applying advanced dressings, compression, or debridement to achieve complete wound closure. In palliative settings, beneficence means maximizing comfort, controlling odor, managing heavy exudate, and alleviating pain.
2. Non-Maleficence (First, Do No Harm): Obligation to avoid inflicting unnecessary pain or harm. Subjecting a dying patient with ischemic limb gangrene to painful, non-beneficial sharp debridements or forced repositioning that causes agonizing pain violates non-maleficence.
3. Autonomy (Respecting Self-Determination): Honoring the informed choices, advance directives, and preferences of competent patients or designated healthcare surrogates regarding comfort care.
4. Justice (Fairness & Resource Allocation): Ensuring equitable access to wound care resources, advanced therapies, and palliative support regardless of patient socioeconomic background.

---

Palliative Wound Care vs. Curative Care

When a chronic wound is determined to be non-healing due to end-stage systemic disease (e.g., severe peripheral arterial disease without revascularization options, terminal cancer, or end-stage heart failure), the treatment goal shifts from wound closure to symptom palliation.

Core Pillars of Palliative Wound Management

• Pain Management: Pre-medicating prior to dressing changes, selecting non-adherent silicone or foam dressings, and applying topical analgesics (e.g., topical morphine gel or compounded lidocaine) directly to painful wound beds.
• Odor Control: Managing malodor caused by anaerobic bacterial proliferation using topical metronidazole (0.75% gel applied to the wound bed), activated charcoal dressings, medical-grade honey, or diluted Dakin's solution (0.125%).
• Exudate Management: Utilizing high-capacity superabsorbent polymer dressings, gelling fiber dressings, or gentle pouching systems to prevent maceration, skin breakdown, and frequent linen changes.
• Infection Suppression: Managing local bioburden with non-cytotoxic topical antimicrobials (cadexomer iodine, silver foam) rather than aggressive systemic antibiotics, unless systemic infection causes distressing symptoms.
• Minimizing Dressing Frequency: Utilizing long-wear, gentle silicone foam dressings to reduce dressing changes to 2 to 3 times per week, minimizing patient disruption.

---

Kennedy Terminal Ulcer (KTU) & Skin Changes at Life's End (SCALE)

A critical legal and ethical distinction in end-of-life care is differentiating an avoidable hospital-acquired pressure injury from an unavoidable Kennedy Terminal Ulcer (KTU) or Skin Changes at Life's End (SCALE).

Pathophysiology of Terminal Skin Failure

Just as cardiac, renal, or pulmonary systems fail during the dying process, the integumentary system undergoes organ failure. Hypoperfusion, microvascular thrombosis, tissue hypoxia, and metabolic shutdown lead to rapid, unavoidable skin necrosis, even when flawless nursing preventative care (repositioning, pressure redistribution) is maintained.

Clinical Features of the Kennedy Terminal Ulcer (KTU)

• Sudden Onset: Appears rapidly over hours to 24–48 hours, often progressing quickly from intact skin to deep tissue destruction.
• Anatomical Location: Predominantly located on the sacrum or coccyx.
• Morphology / Shape: Characteristically shaped like a pear, butterfly, or horseshoe.
• Discoloration (Tri-Color): Displays a mixture of red, yellow, purple, and black tones.
• Prognosis: Indicates imminent death; patients typically succumb within days to weeks of KTU onset.

Ethical Communication & Avoidable vs. Unavoidable Staging

When a KTU or SCALE occurs, clinicians must communicate compassionately with family members, reassuring them that the skin breakdown is a physiological manifestation of organ failure rather than a result of neglect. Documenting the clinical criteria of SCALE protects healthcare staff from unwarranted malpractice allegations of HAPI neglect.

---

Malignant Fungating Wounds (MFWs)

Malignant fungating wounds occur when a primary tumor or metastatic cutaneous deposit infiltrates the epidermis, blood vessels, and lymphatic structures. MFWs present unique clinical and bioethical challenges:

• Pathophysiology: Rapid tumor cell proliferation outgrows blood supply, leading to central tissue necrosis, ulceration, and a cauliflower-like fungating mass.
• Friable Vascularity & Hemorrhage Management: Tumor capillaries are abnormally fragile and lack smooth muscle tone. Minor friction or dressing removal can trigger severe bleeding. Clinicians manage minor oozing with calcium alginate dressings, topical epinephrine (1:1,000 solution on gauze), or tranexamic acid, while avoiding aggressive mechanical cleansing.
• Odor & Exudate Control: Malignant tissue necrosis harbors dense anaerobic bioburden. Applying topical metronidazole gel (0.75%) or activated charcoal dressings with silver is the mainstay of palliative odor control.

---

Surrogate Decision-Making & Advance Directives

When terminal patients lose decision-making capacity, clinicians work with designated Durable Power of Attorney (DPOA) surrogates or follow POLST/MOLST (Physician/Medical Orders for Life-Sustaining Treatment) directives:

• Honoring Patient Autonomy: Surrogates must make decisions based on substituted judgment—reflecting what the patient would have chosen—rather than their own preferences.
• Resolving Conflicts Over Repositioning: Family members may insist on strict 2-hour turning schedules for a dying patient, unaware that turning causes agonizing pain. Clinicians must educate surrogates that comfort-driven micro-repositioning or pressure-relieving air surfaces align with non-maleficence and the patient's palliative goals.
• Avoiding Non-Beneficial Interventions: Clinicians are ethically grounded in declining non-beneficial, painful surgical procedures (e.g., radical operative debridement of a terminal sacral wound) while providing comprehensive comfort care.

Comparison: Curative Wound Care vs. Palliative Care vs. Kennedy Terminal Ulcer